High dose, subcutaneous injections of benzathine penicillin G (SCIP) to prevent rheumatic fever: A single arm, phase IIa trial of safety and pharmacokinetics
SCIP is safe, well tolerated and demonstrates favourable penicillin exposure for most individuals. Future research should explore the effectiveness of SCIP over longer periods and in diverse populations and settings.
Authors
- Anneka Anderson (ORCID: https://orcid.org/0000-0003-0898-5070)
- Laurens Manning (ORCID: https://orcid.org/0000-0003-4334-5351)
- Jonathan Rhys Carapetis (ORCID: https://orcid.org/0000-0002-1182-9792)
- Sam Salman (ORCID: https://orcid.org/0000-0002-8276-6784)
- Michael George Baker (ORCID: https://orcid.org/0000-0002-1865-1536)
- Julie Bennett (ORCID: https://orcid.org/0000-0002-3461-7223)
- Kevin T. Batty (ORCID: https://orcid.org/0000-0003-3850-1778)
- Joseph Kado (ORCID: https://orcid.org/0000-0003-3121-4397)
- Brioni R. Moore (ORCID: https://orcid.org/0000-0001-9792-7838)
- Madhu Page‐Sharp
- Hazel Dobinson (ORCID: https://orcid.org/0000-0002-1092-5715)
- Erik André Andersen
- Dhevindri Moodley
Institutions
- The University of Western Australia (AU)
- Curtin University (AU)
- Princess Margaret Hospital for Children (AU)
- Fiona Stanley Hospital (AU)
- Wellington Hospital (NZ)
- New England Disabled Sports (US)
- Hutt Hospital (NZ)
- University of Otago (NZ)
Publication Details
- Journal
- Journal of Infection
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1016/j.jinf.2025.106506
- Citations
- 6
- Primary Topic
- Streptococcal Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 11.27
Funders
- Cure Kids